TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Scientists at the University of Arizona identified four terpenes from cannabis that effectively relieve pain in animal models without psychoactive effects. This finding opens potential new avenues for treating chronic pain conditions like fibromyalgia and post-surgical pain.
Researchers at the University of Arizona have identified four terpenes from Cannabis sativa that significantly reduce pain in preclinical models of fibromyalgia and post-operative pain without producing psychoactive effects. This discovery could lead to new, non-psychoactive pain treatments, addressing a critical need for safer alternatives to opioids and other medications.
The study, published in Pharmacological Reports, examined four common cannabis terpenes—geraniol, linalool, beta-caryophyllene, and alpha-humulene—and found that all four produced substantial pain-relieving effects in mouse models. Geraniol showed the strongest results, followed by linalool, beta-caryophyllene, and alpha-humulene. These compounds did not induce psychoactive effects, unlike THC, making them promising candidates for medical use.
The research focused on chronic pain conditions like fibromyalgia, which affects up to 5% of the global population and for which treatment options remain limited. The findings suggest that terpenes could be a viable treatment option for this under-treated group. Additionally, the study explored their potential in managing post-surgical pain, which often involves inflammation and heightened sensitivity, and found promising results that could surpass some current options like opioids in safety and efficacy.
Scientists also identified that these terpenes act through the adenosine A2a receptor pathway, which is involved in pain modulation and sedative effects, indicating further research is needed to understand their full potential and safety profile.
Potential Breakthroughs in Non-Psychoactive Pain Relief
This discovery is significant because it offers a potential new class of pain-relief compounds that do not cause the psychoactive effects associated with THC. For millions suffering from chronic pain conditions such as fibromyalgia, these terpenes could provide safer, more effective treatment options. Furthermore, their potential use in post-surgical pain management could reduce reliance on opioids, decreasing the risk of addiction and complications.
While promising, these findings are preclinical, and further research, including clinical trials, is necessary to determine safety, dosage, and efficacy in humans. Nonetheless, this research underscores the importance of exploring natural compounds in developing new medicines.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Black
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
Therabody Theragun Mini 3rd Generation Percussive Massage Gun, Black
As an affiliate, we earn on qualifying purchases.
Natural Compounds and Pain Management Advances
The study builds on earlier research into cannabis compounds, particularly terpenes, which are responsible for the plant’s aroma and flavor. Unlike THC, terpenes do not produce psychoactive effects, making them attractive for medical research. Previous work by the same research team indicated that terpenes could reduce pain related to inflammation and nerve damage, but this is the first study to demonstrate their effectiveness in models of fibromyalgia and post-operative pain.
Natural products have historically been a source of medicinal compounds, with recent successes like the drug semaglutide derived from a compound found in the Gila monster. The current findings reinforce the potential of plant-derived chemicals as sources of new pain treatments and highlight the importance of basic research into plant biochemistry.
“Our research shows that terpenes may be a viable treatment option for fibromyalgia pain, which could make a significant difference for an under-treated population.”
— Dr. John Streicher
What Is Still Unknown About Terpene Safety and Efficacy
While the results in animal models are promising, it remains unclear how these terpenes will perform in humans, including their safety, effective dosages, and potential side effects. The influence of the adenosine A2a receptor pathway on sedative effects and other biological functions also requires further investigation. Clinical trials are needed to confirm these findings and assess their applicability to human medicine.
Next Steps Include Human Trials and Safety Assessments
Researchers plan to conduct clinical trials to evaluate the safety and efficacy of these terpenes in humans. Regulatory approval processes will follow, alongside further studies to optimize dosing and delivery methods. If successful, these compounds could become part of new pain management therapies, reducing reliance on opioids and psychoactive drugs.
Key Questions
Are these terpenes safe for human use?
Safety in humans has not yet been established. Clinical trials are necessary to determine safe dosages and identify any potential side effects.
Could these compounds cause psychoactive effects?
No, the study indicates that these terpenes do not produce psychoactive effects like THC, making them potentially safer for medical use.
Will this lead to new pain medications?
If further research confirms their safety and effectiveness, these terpenes could be developed into new, non-psychoactive pain relief medications.
What conditions could these terpenes treat?
The research focused on fibromyalgia and post-surgical pain, but further studies are needed to explore their use for other chronic pain conditions.
When might these treatments become available?
It is too early to predict; clinical trials and regulatory approval are required before any new treatments reach the market.
Source: Science Daily
